Camel-IDS takes in Series A funding
Camel-IDS, a Belgian developer of cancer-targeted radiopharmaceuticals, has secured 37 million euros in Series A funding. V-Bio Ventures and Gimv led the round with participation from other investors that included HealthCap, Novo Seeds, Pontifax and BioMedPartners.
19 November 2018•1 min read
